Seilern Investment Management Ltd lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 1.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 96,546 shares of the company’s stock after selling 1,014 shares during the quarter. IDEXX Laboratories comprises 6.3% of Seilern Investment Management Ltd’s holdings, making the stock its 6th largest holding. Seilern Investment Management Ltd owned 0.12% of IDEXX Laboratories worth $50,415,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. SHP Wealth Management purchased a new stake in shares of IDEXX Laboratories during the fourth quarter valued at about $26,000. J.Safra Asset Management Corp bought a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at about $25,000. Elevation Wealth Partners LLC grew its position in shares of IDEXX Laboratories by 188.2% in the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after buying an additional 32 shares during the last quarter. Arlington Trust Co LLC grew its position in shares of IDEXX Laboratories by 46.3% in the 2nd quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock worth $32,000 after buying an additional 19 shares during the last quarter. Finally, MV Capital Management Inc. purchased a new position in shares of IDEXX Laboratories in the 4th quarter worth approximately $46,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.
Insider Activity at IDEXX Laboratories
In other news, Director Lawrence D. Kingsley sold 2,203 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the sale, the director owned 9,568 shares of the company’s stock, valued at $5,090,941.44. This trade represents a 18.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.79% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
Check Out Our Latest Research Report on IDEXX Laboratories
IDEXX Laboratories Stock Performance
IDXX stock traded down $1.72 during midday trading on Tuesday, reaching $522.22. The stock had a trading volume of 145,893 shares, compared to its average volume of 567,349. The firm has a fifty day simple moving average of $538.08 and a two-hundred day simple moving average of $552.56. IDEXX Laboratories, Inc. has a 52-week low of $500.61 and a 52-week high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. The stock has a market cap of $41.14 billion, a PE ratio of 36.72, a P/E/G ratio of 2.77 and a beta of 1.55.
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The business had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.20 billion. During the same quarter in the previous year, the business earned $3.50 EPS. The company’s quarterly revenue was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.
IDEXX’s companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.
Featured Stories
- Five stocks we like better than IDEXX Laboratories
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures its Cash Flow Runway
- Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
- IonQ Fell 9% on a $1.3 Billion Deal—Is Wall Street Missing Something?
- JPMorgan Earnings Miss Estimates But Reveal Broad-Based Strength
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
